The ARHGEF4 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cervical carcinoma line. This product provides a heterogeneous pool of cells with targeted disruptions of the ARHGEF4 gene, generated by CRISPR/Cas9-mediated gene disruption. The polyclonal format avoids clonal selection, offering a population-level loss-of-function model that preserves biological variability and is suitable for functional studies where gene knockout effects are assessed at the population level.
HeLa cells are an epithelial carcinoma model harboring HPV-18 E6/E7 oncogenes. E6 degrades p53, while E7 inactivates Rb, leading to immortalization and a highly invasive phenotype. These cells serve as a standard platform for cancer biology and metastasis research, exhibiting robust motility and well-defined signaling networks that facilitate the elucidation of gene function in a transformed context.
ARHGEF4 (Asef) is a Rho guanine nucleotide exchange factor activated by APC downstream of Wnt signaling. Upon Wnt stimulation, Frizzled and Dishevelled relay signals to APC, which then binds and activates ARHGEF4. The exchange factor specifically catalyzes GDP/GTP exchange on Rac1 and Cdc42. GTP-loaded Rac1 and Cdc42 activate effectors including PAK1, the WAVE complex, and Arp2/3, driving actin polymerization and cytoskeletal reorganization. ARHGEF4 also interacts with ??-catenin and F-actin, linking adhesion complexes to the actin machinery. Relevant upstream regulators include Wnt ligands and GSK3??.
In HeLa cells, ARHGEF4-mediated Rac1/Cdc42 activation contributes to invasive motility. Knockout of ARHGEF4 disrupts these pathways, reducing actin-dependent protrusion and migration. Given HeLa’s metastatic properties, this model is relevant for colorectal cancer metastasis research where APC?CARHGEF4 signaling promotes invasion and angiogenesis. The polyclonal knockout helps dissect the contribution of ARHGEF4 to these aggressive traits without clonal bias.
Applications include Transwell migration and invasion assays, F-actin staining with phalloidin, Rac1/Cdc42 activation assays (G-LISA), and Western blotting for phospho-PAK1. Co-immunoprecipitation can examine ARHGEF4 interactions with APC and ??-catenin. The cells are also useful for wound healing assays and drug sensitivity screens targeting Rho GTPase pathways. For more information, contact Ascent Research.
